MAPT and Alzheimer disease: These studies have shown the great interest of these biomarkers, especially t-Tau, P-Tau, and the ratio Aβ42/Aβ40, in the differential diagnosis between AD and DLB, especially at the prodromal stage, where the differential diagnosis is even more delicate [9, 10].